Most free trackers skew full-cap. This is a hand-vetted list of upcoming Phase 2, Phase 3, and PDUFA catalysts in small and micro-cap names only — sourced from SEC filings and company disclosures, not the FDA's own calendar.
Get Access — From $5/MoComing Soon See Sample ListKnow what to watch — and where the financial risk sits.
Vetted small/micro-cap names with a real, dated Phase 2, Phase 3, PDUFA, or equivalent regulatory catalyst ahead — researched directly from SEC filings, investor decks, and company sites.
Being on this list is not a recommendation to buy. Catalysts can go either way or be delayed.
The other side of the same universe — names flagged for dilution risk, thin cash runway, failed-trial history, or going-concern language. Not a recommendation to trade either direction.
This label describes disclosed financial facts only. It is not a recommendation to sell short or take any position.
Two real rows from the list. The rest unlock with a subscription.
| Ticker | Company | Price | Mkt Cap | Catalyst | Detail |
|---|---|---|---|---|---|
| Loading… | |||||
Biotech Trader Handbook is an information publication, not investment advice. Nothing on this site is a recommendation, solicitation or offer to buy, sell or sell short any security. We do not know your finances or goals, and we do not tell any reader what to do.
The "Quality" and "Short-candidate" lists sort publicly disclosed facts, such as trial dates and cash runway. They do not predict price moves and they are not "long" or "short" ideas. A stock on either list can go up or down.
Small and micro-cap stocks are volatile and can lose most or all of their value. Selling short can lose more than the amount invested. Dates and figures come from company filings and can change, slip or contain errors. Verify everything against the original source, and speak to a licensed financial adviser before you trade. Full disclosures.
Two lists, one subscription. Pay monthly or save with the annual plan.
Price lock: your price never goes up while you stay subscribed.